NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC) ...
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...
PHILADELPHIA--(BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells ...
Avoiding many of the pitfalls associated with conventional iPSC reprogramming methods that can introduce genetic instability, PSXi013 has been reprogrammed using our state-of-the-art, footprint-free ...
Market · GlobeNewswire Inc. The induced pluripotent stem cell (iPSC) market is experiencing robust growth, with a projected increase from $3.67 billion in 2025 to $5.75 billion by 2030, achieving a ...
Scientists at the Centre for Genomic Regulation (CRG) and other institutions have published details of a treatment that accelerates the production of female induced pluripotent stem cells (iPSCs) from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results